PMID- 15509134
OWN - NLM
STAT- MEDLINE
DCOM- 20041130
LR  - 20191109
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 21
IP  - 3
DP  - 2004 May-Jun
TI  - In vitro and ex vivo antioxidant activities of labetalol on rabbit neutrophil 
      respiratory burst.
PG  - 178-85
AB  - The beta-adrenoreceptor blocker labetalol has demonstrated important antioxidant 
      properties in vitro that inhibit superoxide anion production during normal 
      leukocyte oxidative metabolism. This study investigated the in vitro and ex vivo 
      effects of labetalol on respiratory burst in rabbit neutrophils. The production 
      of superoxide anions was examined in activated purified rabbit neutrophils after 
      intravenous administration of labetalol (4.0 mg/kg of body weight). At a 
      concentration up to 200 mg/L, labetalol did not demonstrate any cytotoxic effects 
      on neutrophils, as determined by enzyme lactate dehydrogenase activity. In the 
      cell-free system, labetalol demonstrated no significant activity, but in 
      formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated rabbit neutrophils, 
      labetalol demonstrated concentration-dependent antioxidant activity. The in vitro 
      50% inhibitory concentration (IC50) with the fMLP stimulus was 16.5+/-0.21 mg/L 
      in the rabbit neutrophils and 13.2+/-0.16 mg/L in the human neutrophils. In the 
      fMLP-stimulated rabbit polymorphonuclear leukocytes, labetalol demonstrated its 
      peak inhibitory activity (47%) 3 hours after administration. The mechanism by 
      which labetalol acts in the treatment of hypertension may occur from an 
      interaction in the signaling pathway of protein kinase C activation. The 
      antioxidant properties demonstrated in this mechanism contribute to the drug's 
      antihypertensive action and thus, may reduce the risk of injuries inflicted by 
      reactive oxygen species involved in the pathogenesis of hypertension.
FAU - Kouoh, Ferdinand
AU  - Kouoh F
AD  - Laboratory of Pharmacology, Pharmacokinetic and Clinical Pharmacy, Faculty of 
      Biological and Pharmaceutical Sciences, Lille Cedex, France.
FAU - Gressier, Bernard
AU  - Gressier B
FAU - Dine, Thierry
AU  - Dine T
FAU - Luyckx, Michel
AU  - Luyckx M
FAU - Brunet, Claude
AU  - Brunet C
FAU - Ballester, Louis
AU  - Ballester L
FAU - Cazin, Jean Claude
AU  - Cazin JC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 11062-77-4 (Superoxides)
RN  - R5H8897N95 (Labetalol)
MH  - Animals
MH  - Cell Count
MH  - Cell Survival
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Humans
MH  - In Vitro Techniques
MH  - Infusions, Intravenous
MH  - Labetalol/*pharmacology
MH  - Neutrophil Activation
MH  - Neutrophils/*drug effects/physiology
MH  - Rabbits
MH  - Respiratory Burst/*drug effects
MH  - Sensitivity and Specificity
MH  - Statistics, Nonparametric
MH  - Superoxides/analysis/*metabolism
EDAT- 2004/10/29 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/29 09:00
PHST- 2004/10/29 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/29 09:00 [entrez]
AID - 343 [pii]
AID - 10.1007/BF02850123 [doi]
PST - ppublish
SO  - Adv Ther. 2004 May-Jun;21(3):178-85. doi: 10.1007/BF02850123.